Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Catalent Inc (CTLT)

Catalent Inc (CTLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,599,002
  • Shares Outstanding, K 170,227
  • Annual Sales, $ 3,094 M
  • Annual Income, $ 173,000 K
  • 60-Month Beta 1.44
  • Price/Sales 5.91
  • Price/Cash Flow 28.66
  • Price/Book 5.29
Trade CTLT with:

Options Overview

Details
  • Implied Volatility 41.17%
  • Historical Volatility 31.00%
  • IV Percentile 18%
  • IV Rank 13.61%
  • IV High 72.03% on 10/28/20
  • IV Low 36.31% on 07/22/20
  • Put/Call Vol Ratio 65.00
  • Today's Volume 198
  • Volume Avg (30-Day) 509
  • Put/Call OI Ratio 9.26
  • Today's Open Interest 1,241
  • Open Int (30-Day) 4,431

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.72
  • Number of Estimates 5
  • High Estimate 0.80
  • Low Estimate 0.65
  • Prior Year 0.46
  • Growth Rate Est. (year over year) +56.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.08 +7.41%
on 03/25/21
112.04 -4.06%
on 03/23/21
+1.74 (+1.64%)
since 03/12/21
3-Month
97.86 +9.85%
on 03/05/21
127.68 -15.81%
on 02/16/21
-7.25 (-6.32%)
since 01/13/21
52-Week
54.21 +98.29%
on 04/16/20
127.68 -15.81%
on 02/16/21
+52.83 (+96.63%)
since 04/13/20

Most Recent Stories

More News
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.

ZTS : 163.88 (+0.84%)
INFI : 2.97 (-1.00%)
FGEN : 18.89 (-5.03%)
CTLT : 107.13 (-2.06%)
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

JNJ : 157.90 (-2.31%)
PFE : 37.26 (+0.78%)
MRNA : 148.65 (+6.64%)
CTLT : 107.13 (-2.06%)
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna's COVID-19 Vaccine and Clinical Portfolio

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies,...

MRNA : 148.65 (+6.64%)
CTLT : 107.13 (-2.06%)
United Therapeutics (UTHR) Gains on Tyvaso Label Expansion

United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.

MDT : 122.12 (+0.27%)
LLY : 182.35 (+0.29%)
UTHR : 200.77 (+1.10%)
CTLT : 107.13 (-2.06%)
Jazz's (JAZZ) Vyxeos Gets FDA Nod for Pediatric Leukemia

Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.

JAZZ : 162.52 (+0.15%)
USNA : 100.34 (-0.29%)
GWPH : 217.79 (+0.01%)
CTLT : 107.13 (-2.06%)
Time to Focus on Catalent (CTLT) for Strong Earnings Growth Potential

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

CTLT : 107.13 (-2.06%)
Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has signed a drug development agreement...

CLXPF : 1.4900 (+4.56%)
CTLT : 107.13 (-2.06%)
Translate (TBIO) Down on Unsatisfactory CF Drug Study Results

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

SNY : 50.21 (-0.08%)
ZTS : 163.88 (+0.84%)
TBIO : 17.36 (+1.40%)
CTLT : 107.13 (-2.06%)
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

ZTS : 163.88 (+0.84%)
CPRX : 4.30 (+0.23%)
CTLT : 107.13 (-2.06%)
SLNO : 1.1400 (+1.79%)
Catalent (CTLT) Sees Hammer Chart Pattern: Time to Buy?

Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon

CTLT : 107.13 (-2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the...

See More

Key Turning Points

3rd Resistance Point 111.92
2nd Resistance Point 110.86
1st Resistance Point 110.12
Last Price 107.13
1st Support Level 108.32
2nd Support Level 107.25
3rd Support Level 106.51

See More

52-Week High 127.68
Last Price 107.13
Fibonacci 61.8% 99.61
Fibonacci 50% 90.94
Fibonacci 38.2% 82.28
52-Week Low 54.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar